A Dose-Ranging Study of MK-5442 in Postmenopausal Women With Osteoporosis (MK-5442-001)
Status:
Terminated
Trial end date:
2010-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study was to identify an appropriate dose of
MK-5442 that produced an osteoanabolic effect without causing hypercalcemia in postmenopausal
women with osteoporosis.
Phase:
Phase 2
Details
Lead Sponsor:
Merck Sharp & Dohme Corp.
Treatments:
Calcium Calcium Carbonate Cholecalciferol Vitamin D Vitamins